Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06952504 |
Title | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) (TroFuse-033) |
Acronym | TroFuse-033 |
Recruitment | Recruiting |
Gender | female |
Phase | Phase III |
Variant Requirements | Yes |
Sponsors | Merck Sharp & Dohme LLC |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | ISR | ARG |